Biotech Startups
9,608 companies tagged Biotech, with their investors and founders.
ENYO Pharma is a clinical-stage biopharmaceutical company developing therapeutics for patients with impaired kidney function. Its lead compound, VONAFEXOR, is a small molecule with fibrolytic and anti-inflammatory properties in Phase 2 development for rare kidney disease Alport Syndrome and Chronic Kidney Diseases.</parameter> <parameter name="founders">[]
3 investors
EpimAb Biotherapeutics develops bispecific antibody drugs for immuno-oncology and other high-need therapeutic areas using its proprietary FIT-Ig platform, with a pipeline of clinical programs (EMB-01, EMB-06, EMB-07) and preclinical candidates. The company has an R&D center in Shanghai and pursues global licensing and co-development partnerships.
3 investors
Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk. The company uses a platform approach to tune drug candidates across a spectrum from inhibitors to full agonists.
3 investors
Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy. The company's lead compound, EPM-01, is in Phase 1 clinical development for Becker muscular dystrophy.
3 investors
Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform. The company serves patients with difficult-to-treat cancers across oncology.
3 investors
Equator Therapeutics develops first-in-class drugs targeting mitochondrial thermogenesis to treat obesity and metabolic disorders by restoring the body's natural heat production mechanism. The company uses bioelectricity research and high-throughput assays to identify selective activators of thermogenic compounds in mitochondria.
3 investors
Espervita Therapeutics is a drug discovery company developing metabolic reprogramming therapies, with a lead compound (EVT0185) that inhibits acetyl-CoA metabolic enzymes to treat conditions such as MASH, chronic kidney disease, and liver and kidney fibrosis. It focuses on first-in-class small-molecule therapies for metabolic-dysfunction diseases.
3 investors
3 investors
Everbloom develops lab-grown noble fibers from protein waste as sustainable alternatives to animal and synthetic materials for luxury fashion. The company produces fibers with lower environmental impact than wool, cashmere, and silk across land use, water consumption, and emissions.
3 investors
EVOQ Therapeutics develops immunotherapies for autoimmune diseases using its proprietary NanoDisc technology, which delivers disease-specific antigens to dendritic cells via subcutaneous administration to restore native immune tolerance. Its approach targets conditions such as Type 1 diabetes, Celiac disease, Multiple Sclerosis, and Lupus.
3 investors
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases. The therapies target the central nervous system to address the root cause of neurodegeneration.
3 investors
Excelsior Sciences develops automated chemistry technology for small-molecule discovery and manufacturing, targeting pharmaceutical and materials development. Its proprietary Blocc Chemistry platform uses AI-guided synthesis to accelerate drug discovery through machine-readable chemical building blocks and closed-loop learning.
3 investors
ExeVir is a clinical-stage biotech developing single domain antibody (VHH) therapies to prevent and treat infectious diseases, with an initial focus on COVID-19 and dengue. Its modular, multi-specific antibody platform targets vulnerable patients including the immunocompromised.
3 investors
ExpressionEdits builds a computational platform, the Genetic Syntax Engine, that uses AI and intron-based transgene design to improve protein expression for therapeutic applications. The company develops an internal pipeline of therapeutic proteins and works on gene therapy partnerships.
3 investors
Eywa produces clinical-grade psychedelic compounds β including psilocybin, DMT, 5-MeO-DMT, and bufotenine β as APIs and finished drug products made through biosynthesis for use in scientific research, clinical trials, and commercial mental health applications. It also offers a dual-platform app for therapists and patients to personalize and monitor mental health treatment.
3 investors
Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The platform serves hospitals, clinical laboratories, and academic medical centers.
3 investors
Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.
3 investors
Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions. Its pipeline includes drug candidates such as roxadustat and FG-3246.
3 investors
Filtricine is a clinical-stage biotechnology company developing nutrition-based medical food products for disease control, using its Targeted Nutrients Deprivation (TND) approach to starve cancer cells while providing balanced nutrition to patients. Its focus is on "food as medicine" interventions for cancer and other common diseases.
3 investors
1STBIO (νΌμ€νΈλ°μ΄μ€) is a biotechnology company developing drug programs, including the HPK1 inhibitor immuno-oncology candidate FB849 and the NLY02 program. It focuses on advancing therapeutic pipelines to bring treatments to patients.
3 investors
First Light Diagnostics develops the MultiPath benchtop analyzer, an instrument for rapid diagnostic testing. The company operates in the in-vitro diagnostics space.
3 investors
Flare Therapeutics is a drug discovery company developing small molecule therapies that target transcription factors to restore transcriptional control disrupted by cancer. It focuses on treating disease through a class of drug targets previously considered difficult to address.
3 investors
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives. The company focuses on vessel health and blood flow optimization for applications ranging from athletic performance to sexual wellness.
3 investors
Flightpath Biosciences develops Targeted Bacterial Deletion, a platform that selectively removes harmful gram-negative bacteria while sparing the surrounding microbiome to interrupt infection-driven disease. Its pipeline targets bacterial drivers across oral and gastrointestinal diseases, infection-associated cancers, and women's health conditions.
3 investors